Estadístiques de Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial
Visites totals
| views | |
|---|---|
| Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial | 50 |
Visites totals per mes
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| pal-fuo-targ.pdf | 45 |
| pal-fuo-targ.pdf(legacy) | 41 |
Vistes principals per país
| views | |
|---|---|
| United States | 34 |
| Belgium | 6 |
| Spain | 3 |
| Australia | 2 |
| China | 2 |
| India | 2 |
| Argentina | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Boardman | 7 |
| Ann Arbor | 6 |
| San Ramon | 5 |
| Menlo Park | 4 |
| Ashburn | 2 |
| Fairfield | 2 |
| Madrid | 2 |
| Timboon | 2 |
| Barcelona | 1 |
| Mountain View | 1 |
| Mumbai | 1 |
| Rochester | 1 |
| San Diego | 1 |
| Shenzhen | 1 |
| Suipacha | 1 |
| Thane | 1 |